Evidence map›Paper›PMID 35766746›Full record

ArticleRevista peruana de medicina experimental y salud publica

Knowledge, attitudes and practices of pharmacovigilance in the context of COVID-19 in health professionals of the peruvian social insurance.

L Yesenia Rodríguez-Tanta, Diego André Ale-Mauricio, Violeta Saromo-Meléndez, Anaís Lazarte-Ramos, Elisa Gálvez-Dávila, Gisela Pecho-Arias, Jack Urruchi-Huertas, Paola Fernández-Rojas, Raquel Delgado-Escalante

Abstract read
In one paragraph

Article in Revista peruana de medicina experimental y salud publica. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L Yesenia Rodríguez-TantaInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-6510-7795
Diego André Ale-MauricioInstituto Nacional de Salud, Lima, Perú.ORCID http://orcid.org/0000-0001-9377-4440
Violeta Saromo-MeléndezInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-1642-759X
Anaís Lazarte-RamosInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-0917-378X
Elisa Gálvez-DávilaInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0003-4954-5960
Gisela Pecho-AriasInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-5816-5604
Jack Urruchi-HuertasInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-5393-4056
Paola Fernández-RojasInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-0500-2377
Raquel Delgado-EscalanteInstituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima, Perú.ORCID http://orcid.org/0000-0002-0180-2254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aimed to evaluate a group of health professionals' knowledge, attitudes, and practices on pharmacovigilance in the context of COVID-19 in the Peruvian Social Health Insurance (EsSalud). A descriptive secondary analysis was carried out on a database that included responses from an online survey conducted by the Institutional Referral Center for Pharmacovigilance and Technovigilance of EsSalud. Of 144 participants, 66% showed a high level of knowledge and 81.2% had a positive attitude; however, 71.5% had an inadequate level of pharmacovigilance practice. Although EsSalud professionals demonstrated a high level of knowledge and positive attitude to implement pharmacovigilance, this is not reflected in the practice of this activity during the SARS-CoV-2 pandemic. Strategies should be implemented to integrate pharmacovigilance into healthcare activities to benefit patient safety.

Indexed as

COVID-19Drug-Related Side Effects and Adverse ReactionsAttitude of Health PersonnelHealth Knowledge, Attitudes, PracticeHumansPeruPharmacovigilanceSARS-CoV-2Social SecuritySurveys and Questionnaires

Identifiers

PMID35766746
PMCPMC11397595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.